Potential new therapies for the treatment of HIV-1 infection

被引：33

作者：

Condra, JH ^{[1
]}

Miller, MD ^{[1
]}

Hazuda, DJ ^{[1
]}

Emini, EA ^{[1
]}

机构：

[1] Merck Res Labs, West Point, PA 19486 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2002年 / 53卷

关键词：

protease; reverse transcriptase; integrase; entry inhibitors; assembly inhibitors;

D O I：

10.1146/annurev.med.53.082901.104110

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The development and clinical use of chemotherapeutic agents for the treatment of persistent HIV-1 infection over the past decade has profoundly and favorably affected the course of HIV-1 disease for many infected individuals. Unfortunately, the long-term use of these therapies is complicated by unwanted metabolic side effects, by issues of adherence, and by the selection of viral variants with reduced susceptibility. These complications have spurred the search for new anti-HIV-1 agents having improved pharmacological properties and expressing activity against viral variants resistant to the currently available agents. This brief review describes the current state of this search as well as potentially novel viral targets for chemotherapeutic intervention.

引用

页码：541 / 555

页数：15

共 76 条

[21]

ERICKSON JW, 2001, 8 C RETR OPP INF FEB, P46

[22]

ERICKSONVIITANE.SK, 2001, 8 C RETR OPP INF FEB, P46

[23]

ERON J, 2001, 8 C RETR OPP INF FEB, P67

[24] HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase [J].

Espeseth, AS ;

Felock, P ;

Wolfe, A ;

Witmer, M ;

Grobler, J ;

Anthony, N ;

Egbertson, M ;

Melamed, JY ;

Young, S ;

Hamill, T ;

Cole, JL ;

Hazuda, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (21) :11244-11249

[25] HIV integrase structure and function [J].

Esposito, D ;

Craigie, R .

ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :319-333

[26] HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor [J].

Feng, Yu ;

Broder, Christopher C. ;

Kennedy, Paul E. ;

Berger, Edward A. .

JOURNAL OF IMMUNOLOGY, 2011, 186 (11) :872-877

[27] Antagonists of the human CCR5 receptor as anti-HIV-1 agents.: Part 2:: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes [J].

Finke, PE ;

Meurer, LC ;

Oates, B ;

Mills, SG ;

MacCoss, M ;

Malkowitz, L ;

Springer, MS ;

Daugherty, BL ;

Gould, SL ;

DeMartino, JA ;

Siciliano, SJ ;

Carella, A ;

Carver, G ;

Holmes, K ;

Danzeisen, R ;

Hazuda, D ;

Kessler, J ;

Lineberger, J ;

Miller, M ;

Schleif, WA ;

Emini, EA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) :265-270

[28] HIV-1 Gag proteins: Diverse functions in the virus life cycle [J].

Freed, EO .

VIROLOGY, 1998, 251 (01) :1-15

[29] Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules [J].

Gauduin, MC ;

Allaway, GP ;

Maddon, PJ ;

Barbas, CF ;

Burton, DR ;

Koup, RA .

JOURNAL OF VIROLOGY, 1996, 70 (04) :2586-2592

[30]

GRUZDEV B, 2001, 8 C RETR OPP INF FEB, P46

← 1 2 3 4 5 6 7 8 →